Ropinirole: For the treatment of restless legs syndrome

CNS Drugs

Volumn 18, Issue 11, 2004, Pages 747-754

  Cheer, Susan M ^a   Bang, Lynne M ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CYTOCHROME P450 1A2; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; PLACEBO; ROPINIROLE; THEOPHYLLINE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; LEG MOVEMENT; NAUSEA; PHARMACODYNAMICS; PRIORITY JOURNAL; RATING SCALE; RECEPTOR AFFINITY; RESTLESS LEGS SYNDROME; REVIEW; SLEEP; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANTIPARKINSON AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; HUMANS; INDOLES; RESTLESS LEGS SYNDROME;

EID: 4544351925     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418110-00004     Document Type: Review

References (40)

1. Tan E-K, Ondo W. Restless legs syndrome: clinical features and treatment. Am J Med Sci 2000; 319 (6): 397-403
2. Thorpy M, Ehrenberg BL, Hening WA, et al. Restless legs syndrome: detection and management in primary care. Am Fam Physician 2000; 62 (1): 108-14
3. Milligan SA, Chesson AL. Restless legs syndrome in the older adult: diagnosis and management. Drugs Aging 2002; 19 (10): 741-51
4. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 2001 Mar; 18 (2): 128-47
5. Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004; 5 (3): 237-46
6. Weimerskirch PR, Ernst ME. Newer dopamine agonists in the treatment of restless legs syndrome. Ann Pharmacother 2001 May; 35 (5): 627-30
7. Matheson AJ, Spencer CM. Ropinirole: a review of its use in the management of Parkinson's disease. Drugs 2000 Jul; 60 (1): 115-37
8. Murdoch D, Cheer SM, Wagstaff AJ. Management of Parkinson disease: defining the role of ropinirole. Dis Manage Health Outcomes 2004; 12 (1): 39-54
9. Hening WA. Restless legs syndrome: a sensorimotor disorder of sleep/wake motor regulation. Curr Neurol Neurosci Rep 2002 Mar; 2 (2): 186-96
10. 3 receptors [abstract no. 93P]. Br J Pharmacol 1993; 110 Suppl.: 93P
11. Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 1997; 49 Suppl. 1: S58-62
12. Kuzel MD. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease. Am J Health-Syst Pharm 1999; 56: 217-24
13. Jenner P, Tulloch I. The preclinical pharmacology of ropinirole-receptor interactions, antiparkinsonian activity and potential to induce dyskinesia. In: Olanow CW, Obeso JA, editors. Beyond the decade of the brain. Kent: Wells Medical Limited, 1997; 2: 115-28
14. Jost WH, Bellon AK, Kaiser T, et al. The impact of ropinirole on blood pressure and noradrenaline concentration after active orthostasis in Parkinsonian patients. Parkinsonism Relat Disord 1998; 4 (2): 61-3
15. 2-receptor agonist. Br J Clin Pharmacol 1991; 32: 483-8
16. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000 Oct; 39 (4): 243-54
17. Boothman BR, Spokes EGS. Pharmacokinetic data for ropinirole [letter]. Lancet 1990; 336: 814
18. Ramji JV, Keogh JP, Blake TJ, et al. Disposition of ropinirole in animals and man. Xenobiotica 1999; 29 (3): 311-25
19. Levien T, Baker DE. Quetiapine and ropinirole. Hosp Pharm 1998; 33 (5): 556-88
20. Hubble J, Koller WC, Atchison P, et al. Linear pharmacokinetic behavior of ropinirole during multiple dosing in patients with Parkinson's disease. J Clin Pharmacol 2000 Jun; 40: 641-6
21. Brefel C, Thalamas C, Rayet S, et al. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. Br J Clin Pharmacol 1998; 45: 421-15
22. Bloomer JC, Clarke SE, Chenery RJ. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos 1997; 25 (7): 840-4
23. GlaxoSmithKline. Requip® brand of ropinirole hydrochloride tablets [online]. Available from URL: http://www.requip.com [Accessed 2004 Jan 12]
24. Beerahee A, Nichols AI, Aluri J, et al. Population pharmacokinetics of ropinirole in patients with Parkinson's disease. Br J Clin Pharmacol 1997; 43: 556P-7P
25. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004 Jan; 75 (1): 92-7
26. Walters AS, Ondo WG, Dreykluft T, et al. on behalf of the TREAT RLS 2 Study Group. Ropinirole is effective in the treatment of restless legs syndrome: TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004, (In press)
27. Allen RP, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movement and improves sleep parameters in patients with restless legs syndrome. Sleep 2004 Aug; 27 (5): 907-14
28. Haan J, Volc D, Montplaisir J. The long-term management of RLS with ropinirole: maintained efficacy over 36 weeks [abstract no. P1232]. Mov Disord 2004; 19 Suppl. 9: S420
29. Montplaisir J, Karrasch J, Haan J, et al. The impact of ropinirole treatment on health-related quality of life (HRQoL) in patients with RLS: results of a multinational 36-week study [abstract no. P01.080]. Neurology 2004 Apr; 62 (7 Suppl. 5): A54. Plus poster presented at the 56th Annual Meeting of the American Academy of Neurology; 2004 Apr 24-May 1; San Francisco
30. Karrasch J, Haan J, Kruger AJ, et al. Maintained efficacy with ropinirole: results of a multinational 36-week study of patients with RLS [abstract no. 658]. Sleep 2004; 27 Abstract Suppl.: A294
31. Montplaisir J, Karrasch J, Haan J, et al. The impact of ropinirole treatment on RLS symptoms and health-related quality of life (HRQoL) in patients with RLS: results of a multinational 36-week study [abstract no. 656]. Sleep 2004; 27 Abstract Suppl.: A293
32. Adler CH, Hauser R, Sethi K, et al. Ropinirole is beneficial for restless legs syndrome: a placebo-controlled crossover trial. Neurology 2003 Mar 11; 60 (Suppl. 1): 439-40
33. Saletu M, Anderer P, Saletu B, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology 2000; 41 (4): 190-9
34. Saletu B, Gruber G, Saletu M, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 2000; 41 (4): 181-9
35. Ahmed I. Ropinirole in restless leg syndrome. Mo Med 2002; 99 (9): 500-1
36. Estivill E, de la Fuente V. The efficacy of ropinirole in the treatment of chronic insomnia secondary to the restless legs syndrome: polysomnographic data [in Spanish]. Rev Neurol 1999; 29 (9): 805-7
37. Ondo W. Ropinirole for restless legs syndrome. Mov Disord 1999 Jan; 14(1): 138-40
38. Galvez-Jimenez N, Lampuri C, Locker GA, et al. Open label comparative study on the efficacy of pramipexole (PMX) vs. ropinirole (RPN) for the treatment of restless legs syndrome (RLS). Mov Disord 2002; 17 (Suppl. 5): S333
39. Happe S, Sauter C, Klösch G. et al. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology 2003; 48 (2): 82-6
40. Happe S, Trenkwalder C. Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs 2004; 18 (1): 27-36